We document a number of key facts related to trends in COVID-19 vaccination intentions of unvaccinated adults in the United States from April 2021 to January 2022 using the Household Pulse Survey. First, among unvaccinated adults both those who were willing to vaccinate and those who were previously unwilling to vaccinate eventually vaccinated in large numbers.
Division of Science and Public Health Policy
The Division of Science and Public Health Policy is the ASPE lead on public health and biomedical science issues and initiatives, including programmatic and policy areas that involve complex or rapidly evolving science and technology. The Division provides technical assistance on regulatory impact analysis development to HHS agencies and offices. The Division is responsible for policy coordination; long-range planning; legislative development; economic, program, and regulatory analysis; and evaluation focused on the HHS science and public health agencies – the Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), National Institutes of Health (NIH), and Office of the Assistant Secretary for Preparedness and Response (ASPR). Examples of issue areas include:
- Biomedical innovation
- Biomedical research policy
- Medical product regulation
- Drug development, safety, availability, and pricing
- Public health and emergency preparedness, response, and recovery
- Opioid epidemic response
- Emerging infectious diseases
- Prevention of chronic diseases
- Food safety
Reports
Displaying 31 - 40 of 44. 10 per page. Page 4.
Advanced SearchASPE Issue Brief
Demographic Characteristics of Adults Receiving COVID-19 Booster Vaccinations
This ASPE issue brief examines demographic characteristics of adults receiving booster doses of COVID-19 vaccines using data from the U.S. Census Bureau's Household Pulse Survey. As of March 9, 2022, 47.5 percent of the fully vaccinated adult population has received a booster.
Report
Cost of Generic Drug Development and Approval
The purpose of this study was to estimate the cost of generic drug development and approval. This study develops an analytical framework for examining the expected net present value (ENPV) (i.e., the difference between the present value of expected revenues over product life and cost of product development and approval) to a generic drug developer in different size drug markets.
ASPE Issue Brief
Parents’ Intentions to Vaccinate Children for COVID-19 by Child Age: Sociodemographic Factors and Reasons for Hesitancy
This ASPE issue brief examines hesitancy among parents to vaccinate children ages 5-11 and 12-17 using data from the U.S. Census Bureau's Household Pulse Survey. Overall, a larger percent of parents with children aged 5-11 are hesitant to vaccinate their children (34 percent) than parents of children aged 12-17 (21 percent).
ASPE Issue Brief
Variation in use of anti-SARS-CoV-2 monoclonal antibody therapies by social vulnerability and urbanicity
Anti-SARS-CoV-2 monoclonal antibodies are an effective treatment to prevent progression to severe COVID-19 or hospitalization in high-risk individuals. Despite the benefits offered by monoclonal antibody treatment, early reports indicated that these therapeutics were not being widely used.
Research Brief
COVID-19 Vaccination Associated with Reductions in COVID-19 Mortality and Morbidity in the United States, and an Approach to Valuing these Benefits
This ASPE Research Report models the estimated reductions in COVID-19 cases, hospitalizations, and deaths associated with COVID-19 vaccination from December 2020 through July 2021. To download the Research Report, please download the PDF to the right under “Files”. To explore our dashboard that presents the Report’s results, please see below.
ASPE Issue Brief
U.S. Department of Health and Human Services Overdose Prevention Strategy
From 1999 through 2019, there were more than 840,000 drug overdose deaths in the United States. The crisis has continually evolved and escalated, including during the COVID-19 pandemic, when an estimated 93,000 persons lost their lives to drug overdose in 2020--approximately a 30% increase over the year prior.
Report
Addressing Uncertainty in Regulatory Impact Analysis
In 2016, the U.S. Department of Health and Human Services finalized its Guidelines for Regulatory Impact Analysis under the leadership of its Assistant Secretary for Planning Evaluation and Analytics Team. The Guidelines discuss strategies for characterizing the uncertainty in quantified effects as well as the potential impacts of non-quantified effects.
Report
Prescription Drug Supply Chains: An Overview of Stakeholders and Relationships
Many stakeholders and steps are involved in the life cycle of a prescription drug as it moves from chemical synthesis and formulation through dispensing or administration to patients. The specific steps involved in prescription drug supply chains often differ depending on the type of drug, the channel of distribution, and the patient’s source of prescription drug coverage.
Research Brief
Drug Checking Programs in the United States and Internationally: Environmental Scan Summary
This environmental scan presents a review and synthesis of approaches and strategies adopted by drug checking programs and existing evidence on their effectiveness in changing drug use attitudes, behavior, and health outcomes. It includes studies of drug checking programs across a variety of settings in the United States and internationally.